アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Our Abpromise guarantee covers the use of ab13230 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-PTP lambda antibody (ab13223)
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
Lanes 1 to 8: 20
Lanes 5 to 8: blocking peptide used at 1
Lane 1: Human Brain Lysate
Lane 2: Human Kidney Lysate
Lane 3: Human Pancreas Lysate
Lane 4: Human Heart Lysate
Lane 5: Human Brain Lysate + blocking peptide (ab13230)
Lane 6: Human Kidney Lysate + blocking peptide (ab13230)
Lane 7: Human Pancreas Lysate + blocking peptide (ab13230)
Lane 8: Human Heart Lysate + blocking peptide (ab13230)
A weak band of predicted size (~160kDa) is observed in human kidney lysate which is quenched by the blocking peptide (ab13230).
ab13230 has not yet been referenced specifically in any publications.